Yu-Jet’s CDSS integrates clinical data, AI algorithms, and medical knowledge bases to assist clinicians in diagnosis and treatment decision-making — enhancing clinical efficiency and patient safety.
The system analyzes real-world data such as disease characteristics, treatment responses, and drug interactions, and is fully integrated with Yu-Jet’s drug portfolio.
Applications include：
AI-based seizure pattern recognition and treatment-response tracking for precision dose adjustment.
Integration of serum and urinary copper data to provide personalized treatment insights and long-term monitoring.
Image and biomarker analysis to detect early myocardial injury and recommend therapeutic adjustments.
Through the dual pillars of pharmaceutical innovation and digital health technology, Yu-Jet continues to build an ecosystem of “Drug × AI Clinical Decision Support” that enhances clinical precision, physician confidence, and patient outcomes.
This multimodal platform combines EEG and full-body pressure sensing to measure neuromuscular coordination, balance, and mobility performance.
It is designed for use in sarcopenia management, aging assessment, and rehabilitation monitoring, translating physiological data into meaningful clinical insights that support precision diagnostics and continuous patient care.